ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 100 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $24,341,000 | +9.7% | 469,264 | 0.0% | 4.28% | -15.7% |
| Q2 2022 | $22,182,000 | -33.6% | 469,264 | 0.0% | 5.08% | -35.7% |
| Q1 2022 | $33,402,000 | +15.3% | 469,264 | +21.1% | 7.90% | -17.3% |
| Q4 2021 | $28,970,000 | +60.9% | 387,400 | +22.2% | 9.55% | +45.8% |
| Q3 2021 | $18,006,000 | +129.8% | 316,952 | +78.0% | 6.55% | +103.2% |
| Q2 2021 | $7,836,000 | -7.2% | 178,058 | +4.0% | 3.22% | -9.4% |
| Q1 2021 | $8,441,000 | +33.3% | 171,147 | +13.8% | 3.56% | +57.1% |
| Q4 2020 | $6,333,000 | -14.7% | 150,433 | -7.3% | 2.26% | -28.0% |
| Q3 2020 | $7,427,000 | -13.0% | 162,236 | -4.5% | 3.15% | -17.3% |
| Q2 2020 | $8,533,000 | -2.4% | 169,949 | 0.0% | 3.81% | -28.2% |
| Q1 2020 | $8,740,000 | -12.6% | 169,949 | +4.9% | 5.30% | -12.6% |
| Q4 2019 | $10,005,000 | – | 161,949 | – | 6.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 825,329 | $37,784,000 | 12.03% |
| Fairmount Funds Management LLC | 162,236 | $7,427,000 | 3.15% |
| ARMISTICE CAPITAL, LLC | 524,000 | $23,989,000 | 0.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $81,260,000 | 0.56% |
| Granahan Investment Management | 188,164 | $8,614,000 | 0.29% |
| Virtus ETF Advisers LLC | 12,046 | $551,000 | 0.29% |
| Soleus Capital Management, L.P. | 11,500 | $526,000 | 0.28% |
| Matarin Capital Management, LLC | 28,453 | $1,303,000 | 0.27% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 248 | $11,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $206,000 | 0.19% |